Key facts

Active substance
(R)-2-[3-({Benzoxazol-2-yl[3-(4-methoxyphenoxy)propyl]amino}methyl)phenoxy]butanoic acid
Therapeutic area
Cardiovascular diseases
Decision number
PIP number
Pharmaceutical form(s)
Film-coated tablet
Condition(s) / indication(s)
Reduction of residual cardiovascular events in patients with diabetes
Route(s) of administration
Oral use
Contact for public enquiries
Kowa Research Europe Ltd 
United Kingdom 
E-mail: regulatory@kowa.co.uk 
Tel. +44 (0)1189 229 000
Decision type
RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)


How useful was this page?

Add your rating